AusBiotech 2011: Dealing with the dragon
13 October, 2011 by Tim DeanThe growth of China’s life sciences sector presents tremendous opportunities for Australian biotechs, but it pays to understand the nuances of the culture and take things slow.
Going green: Life Scientist of the Year
12 October, 2011 by Tim DeanAssociate Professor Min Chen from The University of Sydney has been awarded the Prime Minister’s Prize for Life Scientist of the Year.
Into the pits: clathrin inhibiters licensed to UK biotech
11 October, 2011 by Tim DeanThe CMRI, University of Newcastle and Freie Universitaet Berlin have licensed their newly-developed clathrin inhibitors to Ascent Scientific in the UK.
Experimental DNA vaccine gives full protection against herpes
11 October, 2011 by Tim DeanCoridon has announced the results of a pre-clinical animal study of new DNA vaccine showing 100% protection against herpes simplex virus 2.
Feature: Small is big in drug delivery
07 October, 2011 by Fiona WylieGood things really do come in small packages, and they don't come much smaller than the nano-containers being developed by Frank Caruso's team in Melbourne.
Biotron kicks off trial of novel HIV treatment
05 October, 2011 by Staff WritersProof-of-concept human trial of HIV drug BIT225 has commenced, with results expected in the first quarter of 2012.
Mesoblast and Lonza partner to mass-produce stem cells
27 September, 2011 by Tim DeanLonza to manufacture commercial quantities of Mesoblast’s adult stem cells with an option for Mesoblast to buy purpose-built manufacturing facility.
Prana trial gains interest from Huntington’s disease community
16 September, 2011 by Staff WritersInternational Huntington's disease patients groups have expressed strong interest in upcoming phase II trials of Prana’s treatment.
HealthLinx makes a push into Chinese market
09 September, 2011 by Staff WritersHealthLinx has partnered with Chinese CRO with a vision to launching ovarian cancer treatment, OvPlex, into Chinese market.
Alchemia kicks off phase II lung cancer trial
09 September, 2011 by Staff WritersA phase II trial of anti-cancer drug, HA-Irinotecan, for the treatment of small cell lung cancer, has commenced in Melbourne.
Feature: Building better drugs
07 September, 2011 by Fiona WylieEureka Award winner, Associate Professor Kevin Pfleger, straddles the worlds of academia and biotechnology, helping to apply his findings for the lab to producing better drugs.
Immuron moves to human trials for influenza drug
30 August, 2011 by Staff WritersPhase I/IIa human trials for Immuron’s (ASX:IMC) IMM 255 immunotherapy for influenza will take place in Israel.
QRxPharma advances with NDA for MoxDuo IR
25 August, 2011 by Staff WritersQRxPharma (ASX:QRX) has completed its New Drug Application submission with the FDA, one of the last hurdles before being given regulatory approval.
Feature: Genetics and the origins of modern cotton
24 August, 2011 by Graeme O'NeillProfessor Jonathan Wendel is retracing the genetic changes to cotton that have occurred over more than 5000 years of domestication.
R&D Tax Credit clears Senate
23 August, 2011 by Tim DeanThe much-debated and long-delayed R&D Tax Credit has been given the go-ahead by the Senate, although it still needs to go through the House of Representatives for any amendments.
